Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Stage IV Non-small Cell Lung Cancer (NSCLC)|Recurrent Non-small Cell Lung Cancer (NSCLC)|Extensive-stage Small Cell Lung Cancer (SCLC)|Recurrent Small Cell Lung Cancer (SCLC)|Tumors Metastatic to Brain|Metastatic Breast Cancer (mBC)
Interventions: DRUG: Pegylated Irinotecan
Sponsor: Joel Neal
Collaborators: Nektar Therapeutics